Prof Anders Bjartell.

Anders Bjartell MD, PhD FEBU graduated from Lund University Medical School, Sweden, in 1986. He was a research fellow at the National Institutes of Health in Bethesda, Maryland, USA, from 1988 to 1989, and received his PhD in Medical Cell Research from Lund University in 1990. After training at the University Hospital in Malmö, he became Specialist in Urology in 1998, and received his Fellows of the European Board of Urology (FEBU) diploma in 1999. He was appointed Associate Professor at Lund University in 1995. In 2006, Professor Bjartell became full Professor in Clinical Urology, and Senior Consultant at Skåne University Hospital in Malmö.

Professor Bjartell was a Clinical Investigator at the Department of Urology, Memorial Sloan Kettering Cancer Center in New York, USA, from 2005 to 2007, he has been Associate Editor for European Urology from 2005 to 2012, president and board member of the European Association of Urology (EAU) Section of Urological Research (ESUR) and he is now Chairman of the EAU Research Foundation and Board member of the EAU Guidelines Office.

Professor Bjartell is also a national principal investigator for several trials of new drugs in metastatic prostate cancer and Head of the clinical trial unit at the Urology Department at Skåne University Hospital. He leads a research group in translational prostate cancer research with long term experience in prostate cancer biomarkers. He has participated in several EU-sponsored prostate cancer projects, and he was co-PI of PIONEER, Big Data in Prostate Cancer and he is clinical lead for prostate cancer in OPTIMA, Tackling Cancer through Real World Data and Artificial Intelligence.

Prof Bjartell has published more than 396 peer reviewed articles (Pubmed) and 501 in Web-of-Science with an H-index of 67.